Overall, 96% of patients showed complete response after the first course of rituximab (defined as Hb >120 g/L for haemolytic anemia and platelet count >100 x 109/L for patients with thrombocytopenia). The gene discussed is GSTM1; the disease is Thrombocytopenia.